Hydrazide derivatives as prostaglandin receptors modulators

Details Hydrazide derivatives as prostaglandin receptors modulators Hydrazide derivatives as prostaglandin receptors modulators

2004-07-16

2008-12-16

Solola, Taofiq A (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Ester doai

C560S022000, C560S023000

Reexamination Certificate

active

07465755

ABSTRACT:
The present invention relates to hydrazide derivatives of Formula I notably for use as pharmaceutically active compounds, as well as to pharmaceutical formulations containing such hydrazide derivatives. Said hydrazide derivatives are useful in the treatment of preterm labor, dysmenorrhea, fertility disorders, asthma, hypertension, undesired blood clotting, preelampsia, eclampsia, an eosinophil disorder, undesired bone loss, renal dysfunction, an immune deficiency disorder, ichthyosis, elevated intraocular pressure, infertility, sexual dysfunction, gastric ulcers and inflammatory disorders.

REFERENCES:
patent: 1 114 816 (2001-07-01), None
patent: 99 02164 (1999-01-01), None
patent: 99 33794 (1999-07-01), None
patent: 00 03980 (2000-01-01), None
patent: 01 46140 (2001-06-01), None
patent: 02 24647 (2002-03-01), None
patent: 02 42268 (2002-05-01), None
Abramovitz et al. “The utilization of recombinant prostanoid receptors to determine the affinities and selectivities of prostaglandins and related analogs”, Biochimica et Biophysica Acta, vol. 1483, pp. 285-293 2000.
Benoit et al. “Latest discoveries in prostaglandin receptor modulators”, Expert. Opin. Ther. Patents, vol. 12, No. 8, pp. 1225-1235 2002.
Choung et al. “Role of EP2 Receptors and cAMP in Prostaglandin E2 Regulated Expression of Type I Collagen alpha1, Lysyl Oxidase, and Cyclooxygenase-1 Genes in Human Embryo Lung Fibroblasts”, Journal of Cellular Biochemistry, vol. 71, pp. 254-263 1998.
Coleman et al. “Prostanoids and their Receptors”, In Comprehensive Medicinal Chemistry, The rational Design, Machanistic Study and Therapeutic Application of Chemical Compounds, vol. 3, pp. 643-714 1989.
Coleman et al. “VIII. International Union of Pharmacology Classification of Prostanoid Receptors: Properties, Distribution, and Structure of the Receptors and Their Subtypes”, Pharmacological Reviews, vol. 46, No. 2, pp. 205-229 1994.
Fleisch et al. “LY171883, 1-<2-Hydroxy-3-Propyl-4-<4-(1H-Tetrazol-5-yl) Butoxy>Phenyl>Ethanone, an Orally Active Leukotriene D4 Antagonist”, Journal of Pharmacology and Experimental Therapeutics, vol. 233 No. 1, pp. 148-157 1985.
Formica et al. “Comparative Assessment of Bone Mineral Measurements Using Dual X-ray Absorptiometry and Peripheral Quantitative Computed Tomography”, Osteoporos Int, vol. 8, pp. 460-467.
Hyman et al. “Oral prostaglandin (PGE2) therapy for chronic viral hepatitis B and C”, Journal of Viral Hepatitis, vol. 6, pp. 329-336 1999.
Meltzer et al. “Substituted 3-Phenyltropane Analogs of Cocaine: Synthesis, Inhibition of Binding at Cocaine Recognition Sites, and Positron Emission Tomography Imaging”, J. Med. Chem. vol. 36, pp. 855-862 1993.
Miyaura, “Role of EP4 receptor in bone resorption induced by PGE”, Folia Pharmacol. Jpn., vol. 117, pp. 293-297 with partial English translation 2001.
De Mico et al. J. Org. Chem., vol. 62, pp. 6974-6977 1997.
Levi et al. “Regulation of Prostanoid synthesis in microglial cells and effects of prostaglandin E2 on microglial functions”, Biochemie, vol. 80, pp. 899-904 1998.
Gao et al. “Catalytic Asymmetric Epoxidation and Kinetic Resolution: Modified Procedures Including in Situ Derivatization”, J. Am. Chem. Soc., vol. 109, pp. 5765-5780 1987.
Katsuki et al. “Synthesis of Saccharides and Related Polyhydroxylated Natural Products. 2. Simple Deoxyalditols”, J. Org. Chem., vol. 47, pp. 1378-1380 1982.
Takayama et al. “Prostaglandin E2 Suppresses Chemokine Production in Human Macrophages through the EP4 Receptor”, Journal of Biological Chemistry, vol. 277, No. 46, pp. 44147-44154.
Tsugeno et al. “Vertebral Fracture and Cortical Bone Changes in Corticosteroid-Induced Osteoporosis”, Osteoporos Int, vol. 13, pp. 650-656 2002.
Ushikubi et al. “Roles of Prostanoids Revealed From Studies Using Mice Lacking Specific Prostanoid Receptors”, Jpn. J. Pharmacol., vol. 83, pp. 279-285 2000.

Affiliated with

Also associated with

Rating

Hydrazide derivatives as prostaglandin receptors modulators does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Hydrazide derivatives as prostaglandin receptors modulators, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Hydrazide derivatives as prostaglandin receptors modulators will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4024776